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Background: Lipoprotein (a) [Lp(a)] is an emerging lipid risk factor with potent atherogenic properties. The ability of Lp(a) levels to predict an 
adverse cardiovascular outcome in patients presenting for cardiac catheterization has not been examined.
Methods: Serum Lp(a) levels were determined in 2,769 patients who underwent elective coronary angiography without evidence of myocardial 
necrosis and ischemic cardiovascular events in the next 30 days. The relationship between Lp(a) levels and both the extent of angiographic disease 
and the 3-year incidence of major adverse cardiovascular events (MACE: death, myocardial infarction, stroke and coronary revascularization) was 
investigated.
Results: Patients (stenosis >50% in 91.8%, 3-vessel disease 42.5%, 3-year MACE 36.6%) had a median Lp(a) of 16.4 mg/dL. 37.9% of 
patients had a clinically elevated Lp(a) >=30 mg/dL. These patients were younger (63.0±10.7 vs. 63.9±10.9 years, p=0.04), more likely to have 
hyperlipidemia (90.8 vs. 87.9%, p=0.02), previous myocardial infarction (53.7 vs. 49.2%, p=0.03) and be treated with a statin (72.3 vs. 63.1%, 
p<0.001). The presence of an elevated Lp(a) was associated with a 2.3-fold (95% CI, 1.7-3.2, p<0.001) greater likelihood of having a significant 
angiographic stenosis (>50%) and 1.5-fold (95 CI, 1.3-1.7, p<0.001) greater chance of 3-vessel disease. Lp(a) >=30 mg/dL was also associated 
with a greater rate of MACE (41.8 vs. 35.8%, p=0.005), which was due to a greater rate of need for coronary revascularization (30.9 vs. 26.0%, 
p=0.02). The relationship between Lp(a) levels and cardiovascular outcome was observed in patients with a LDL-C >=70-100 mg/dL (p=0.049) and 
>100 mg/dL (p=0.02), but not <70 mg/dL (p=0.77).
Conclusion: In stable patients undergoing elective coronary angiography Lp(a) levels correlate with the extent of obstructive disease and predicts 
the subsequent incidence of need for coronary revascularization in patients with suboptimal control of LDL-C. This supports the need to intensify 
lipid management in patients with elevated Lp(a) levels.
